This trial is evaluating whether Quality-of-Life Assessment will improve 1 primary outcome, 5 secondary outcomes, and 3 other outcomes in patients with Paraganglioma. Measurement will happen over the course of Monthly, up to 17 months..
This trial requires 3 total participants across 1 different treatment group
This trial involves a single treatment. Quality-of-Life Assessment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"There is considerable tension inherent in a study of psychological outcomes. However, to minimize this tension, and to minimize the potential impact on the study's internal validity, quality-of-life assessment is highly recommended during clinical trials as one of the best outcome measures." - Anonymous Online Contributor
"This case highlights the importance of genetic testing for the diagnosis of metastasizing extra-adrenal pheochromocytoma in family members of a patient with a nonfunctioning adrenal pheochromocytoma." - Anonymous Online Contributor
"Given the large number of inherited conditions known to predispose to pheochromocytoma, geneticists suspect that pheochromocytoma will be found to have an additional hereditary cause in the future. The possibility that the "first tumor" of a multiple endocrine neoplasia (MEN) syndrome is actually a pheochromocytoma warrants further investigation." - Anonymous Online Contributor
"Symptoms of hypertension, sweating, palpitations, and increased appetite or weight loss are possible, and can occur in pheochromocytoma, with paroxysmal, episodic, or chronic events. The only conclusive symptom of pheochromocytoma is high blood pressure." - Anonymous Online Contributor
"A pheochromocytoma is a rare tumor that arises in the adrenal medulla, which is normally located within the adrenal gland. It was first identified by the English physician Henry Maudsley in 1873; in his memoirs, Maudsley said that he first noticed an unusual abdominal pain and syncope when he was working as an assistant to the famed surgeon Charles Bright. Maudsley described in detail the features of this rare tumor. However, the cause of this tumor was identified in 1933, when it was reported to have arisen from the chromaffin cells in the adrenal glands of a 40-year-old man." - Anonymous Online Contributor
"About 70,000 pheochromocytomas, including both sporadic and familial forms, are diagnosed annually in the United States. This disorder is, therefore, one of the most frequent endocrine tumors in the country. We consider pheochromocytoma a rare disease, but must evaluate all patients, including those whose tumor is not easily noticed, because it is still the most common endocrine tumor." - Anonymous Online Contributor
"This paper discusses the indications for adrenalectomy, the potential effects of resection on cancer control and adrenal gland function, and the role of adrenalectomy in the management of patients with pheochromocytoma." - Anonymous Online Contributor
"Pheochromocytoma is treated with dopamine-releving agents such as aminorex, pyridoxal-5'-phosphate, levodopa with a peripheral dopamine receptor antagonist such as alpha-methyl-D-tyrphenylalanine, and alpha-methyl-D-tyrosine in addition to alpha-dihydrotetrabenazine and metaiodobenzylguanidine as part of multidisciplinary treatment." - Anonymous Online Contributor
"The average age of diagnosis (47 years) is well below what would be expected, and has had repercussions on both the patient's and their family's well-being throughout the duration. Therefore, prompt diagnosis and treatment are necessary to ensure that patients have the best possible outcomes. At the same time, research should be made to determine whether these patients would benefit from a periodic surveillance regimen of abdominal imaging." - Anonymous Online Contributor
"Because this tumor can produce significant, disabling symptoms, it is essential that the clinician not delay diagnosis. [If your symptoms did not improved on dietary exclusion, then your pheochromocytoma must be tested. If it is found that these symptoms were caused by a high blood pressure unrelated to diabetes, treatment will require an early diagnosis, a sympathomimetic drug, and follow-up with another blood pressure test. If the patient continues to have these symptoms for more than one month, the clinician should evaluate other possible causes to rule out alternative diagnoses; if other possible diseases can not be ruled out, then surgical removal may be appropriate. For patients whose symptoms have persisted despite ongoing treatment, surgical removal could be considered." - Anonymous Online Contributor
"In this population study of patients referred for a head and/or neck CT, the prevalence of clinically significant and/or life-threatening intracranial tumors was relatively<3% in symptomatic patients with a mean age of 60 years. These imaging findings could potentially prompt a surgical intervention." - Anonymous Online Contributor
"Patients with pheochromocytoma or Cushing's syndrome report similar changes in HRQOL from treatment that improves symptoms, and treatment may be particularly effective for those with diabetes. However, HRQOL for patients with pheochromocytoma decreases after completion of treatment, and improvement of symptoms in patients with Cushing's syndrome, unlike that in patients with diabetes, may be attributable to improved comorbidities rather than treatment. HRQOL may play an important role in decision making in the evaluation and treatment of patients with pheochromocytoma and Cushing's syndrome." - Anonymous Online Contributor